Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibroblast Growth Factor Receptor 2 (FGFR2) is a receptor tyrosine kinase that binds fibroblast growth factors (FGFs). The FGFR2c isoform is an alternative splice variant predominantly expressed in mesenchymal tissues. It plays critical roles in embryonic development, tissue repair, and angiogenesis. Upon FGF binding, FGFR2c activates intracellular signaling pathways, including Ras/MEK/MAPK and PI3K/Akt, leading to cell proliferation, differentiation, migration, and survival. Dysregulation or mutation of FGFR2c has been implicated in various cancers and developmental disorders. Small-molecule inhibitors targeting the kinase domain have been developed for cancer therapy.
Tyrosine kinase inhibition
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibroblast Growth Factor Receptor 2c (None).